Ellansé M

Ellansé M is a sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial ageing signs or conditions. Its principal component is synthetic Poly-e-caprolactone (PCL) microspheres suspended in a carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose (CMC), in a ratio of 30% PCL microspheres to 70% gel carrier.

It works through a dual action: immediate filling from the CMC-based carrier gel, which is resorbed 2 to 3 months after injection, followed by progressive stimulation of the patient's own collagen, predominantly type I, by the PCL microspheres. Within the range, Ellanse M is the option for more extensive volume augmentation, where Ellanse S is the option for minimal augmentation. M offers 24 months of longevity against 18 months for S, a difference that comes from the longer PCL chain length in the M microspheres.

Ellansé M is supplied as 2 x 1 mL ready-to-use syringes with four 27G needles in the pack, and is a Class III medical device CE marked since 2009 under Medical Device Directive 93/42/EEC. ALLPARA supplies it to clinics and licensed practitioners with batch-level traceability and documentation available on request. Ellanse M price is quoted to registered professional buyers on request, together with stock status and delivery options.

• Immediate correction of facial volume loss from the carboxymethylcellulose carrier gel, which is resorbed 2 to 3 months after injection
• Progressive stimulation of the patient's own collagen, predominantly type I, by the polycaprolactone microspheres
• 30% PCL microspheres to 70% CMC-based carrier gel, with a microsphere diameter of approximately 100 microns
• 24 months of longevity, against 18 months for Ellanse S, the two being distinguished only by the initial polymer chain length of the PCL
• 100% of patients treated with Ellanse M had improved, much improved or very much improved results at 24 months
• The option for more extensive volume augmentation within the Ellanse family, where Ellanse S is the option for minimal augmentation
• Treats upper, mid and lower face: forehead, temples, brow, nose, cheeks, nasolabial folds, oral commissures, marionette lines, chin and jawline
• Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
• Supplied as 2 x 1 mL ready-to-use syringes with four 27G needles
• Class III medical device, CE marked since 2009, legal manufacturer AQTIS Medical B.V., Utrecht, Netherlands, for Sinclair

Indications and Professional Use

Main indications

• Subdermal implantation in the face for the lasting correction of wrinkles and facial ageing signs or conditions
• Correction of age-related volume loss due to increased skin laxity, fat loss and diminished support from underlying muscle and bone
• More extensive volume augmentation, which is the position of Ellanse M within the range

Professional use

This product is supplied for administration by qualified medical practitioners only, within the scope of their professional registration and local regulations for injectable medical devices. It is a stand-alone device and is not required to be used in combination with any other device to meet its intended purpose. Injection technique, plane and volume are determined by the treating practitioner on a per-patient basis, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Selection between Ellanse S and Ellanse M is a decision about the degree of correction and the longevity required, and the two must not be treated as interchangeable. Each unit is sterile and for single use only.

Treatment areas

• Upper face: forehead, temples, brow area
• Mid face: nose reshaping, cheek augmentation, nasolabial folds
• Lower face: oral commissures, marionette lines, chin definition, jawline
• Injected subdermally, into the subcutaneous fat or hypodermis, with modalities recommended per facial region and per area

Patient profile

Intended for adult patients over 18 who are not pregnant or breast-feeding and who are deemed appropriate for treatment by the physician. Because polycaprolactone is a bioresorbable implant rather than a hyaluronic acid gel, patient selection and expectation setting carry additional weight and are determined by the practitioner at consultation. Contraindications, warnings and precautions must be reviewed in the product leaflet before treatment.

How Ellansé M Works

Why Order From Allpara

Allpara offers genuine, verified ELLANSÉ products from vetted suppliers, with full batch-traceability and expert support. We serve clinics and aesthetic professionals with CE-certified products, fast EU-wide delivery from our EU warehouse, and competitive trade pricing. Our focus is your patients' safety, satisfaction and results - with dedicated after-sales support for your peace of mind.

Frequently Asked Questions